Literature DB >> 19774621

Clinical and molecular characterization of S1118F-CFTR.

Himabindu Penmatsa1, Carla A Frederick, Sunitha Nekkalapu, Veronica G Conoley, Weiqiang Zhang, Chunying Li, John Kappes, Dennis C Stokes, Anjaparavanda P Naren.   

Abstract

BACKGROUND: Cystic fibrosis is a lethal autosomal recessive disorder usually associated with lung disease, pancreatic insufficiency and high sweat chloride levels. CLINICAL CASE: A patient admitted to Le Bonheur Children's Medical Center (LBCMC, Memphis, TN) showed symptoms of meconium ileus which required exploratory laparotomy, bowel resection and ileostomy. Genotyping showed DeltaF508/I1027T on one chromosome and S1118F on the other. Sweat testing on three different occasions gave negative and intermediate results (22.7, 24.6 mmol/L; 55.1, 58.6 mmol/L and 55.1, 58 mmol/L) and pancreatic elastase testing showed normal levels.
OBJECTIVE: To characterize S1118F-CFTR mutation at a molecular level to help understand the associated CF-phenotype.
METHODS: Molecular characterization of S1118F-CFTR mutant was studied in HEK-293 cells at 37 degrees C. Various biochemical methods such as Western blotting, real-time PCR, Pulse chase labeling and iodide efflux assay were employed.
RESULTS: S1118F-CFTR makes less than 10-15% of mature CFTR (band C) compared to WT-CFTR. The mRNA levels of S1118F-CFTR and WT-CFTR are comparable. S1118F-CFTR is functional but shows about 10-15% of WT-CFTR activity. S1118F-CFTR shows impaired maturation and CF-correctors can increase the amount of mature and functional CFTR by three- to fourfold.
CONCLUSION: S1118F-CFTR shows impaired maturation and an individual with S1118F-CFTR paired with DeltaF508-CFTR exhibits atypical CF symptoms with intermediate sweat chloride level and meconium ileus despite documented pancreatic sufficiency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19774621      PMCID: PMC2821577          DOI: 10.1002/ppul.21092

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  18 in total

1.  CFTR folding and maturation in cells.

Authors:  Mohamed Benharouga; Manu Sharma; Gergely L Lukacs
Journal:  Methods Mol Med       Date:  2002

2.  Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones.

Authors:  Ying Wang; M Claire Bartlett; Tip W Loo; David M Clarke
Journal:  Mol Pharmacol       Date:  2006-04-19       Impact factor: 4.436

Review 3.  Genotype and phenotype in cystic fibrosis.

Authors:  J Zielenski
Journal:  Respiration       Date:  2000       Impact factor: 3.580

4.  Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings.

Authors:  I Bronsveld; F Mekus; J Bijman; M Ballmann; H R de Jonge; U Laabs; D J Halley; H Ellemunter; G Mastella; S Thomas; H J Veeze; B Tümmler
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

5.  C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation.

Authors:  M Haardt; M Benharouga; D Lechardeur; N Kartner; G L Lukacs
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

Review 6.  Assembly of functional CFTR chloride channels.

Authors:  John R Riordan
Journal:  Annu Rev Physiol       Date:  2005       Impact factor: 19.318

7.  Interaction between permeation and gating in a putative pore domain mutant in the cystic fibrosis transmembrane conductance regulator.

Authors:  Z R Zhang; S I McDonough; N A McCarty
Journal:  Biophys J       Date:  2000-07       Impact factor: 4.033

8.  Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein.

Authors:  Ying Wang; Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  J Biol Chem       Date:  2007-10-02       Impact factor: 5.157

9.  COOH-terminal truncations promote proteasome-dependent degradation of mature cystic fibrosis transmembrane conductance regulator from post-Golgi compartments.

Authors:  M Benharouga; M Haardt; N Kartner; G L Lukacs
Journal:  J Cell Biol       Date:  2001-05-28       Impact factor: 10.539

10.  Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions.

Authors:  Chunying Li; Keanna S Dandridge; Anke Di; Kevin L Marrs; Erica L Harris; Koushik Roy; John S Jackson; Natalia V Makarova; Yuko Fujiwara; Patricia L Farrar; Deborah J Nelson; Gabor J Tigyi; Anjaparavanda P Naren
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

View more
  6 in total

1.  A young Hispanic with c.1646G>A mutation exhibits severe cystic fibrosis lung disease: is ivacaftor an option for therapy?

Authors:  Sunitha Yarlagadda; Weiqiang Zhang; Himabindu Penmatsa; Aixia Ren; Kavisha Arora; Anjaparavanda P Naren; Fatima Anmol I Khan; Catherine A Donnellan; Saumini Srinivasan; Dennis C Stokes; John C Kappes
Journal:  Am J Respir Crit Care Med       Date:  2012-10-01       Impact factor: 21.405

Review 2.  Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas.

Authors:  Weiqiang Zhang; Naoaki Fujii; Anjaparavanda P Naren
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

Review 3.  Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.

Authors:  Misak Harutyunyan; Yunjie Huang; Kyu-Shik Mun; Fanmuyi Yang; Kavisha Arora; Anjaparavanda P Naren
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-12-14       Impact factor: 5.464

4.  Murine and human CFTR exhibit different sensitivities to CFTR potentiators.

Authors:  Guiying Cui; Nael A McCarty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-07-24       Impact factor: 5.464

5.  Detecting Common CFTR Mutations by Reverse Dot Blot Hybridization Method in Cystic Fibrosis First Report from Northern Iran.

Authors:  Mohammad-Reza Esmaeili Dooki; Haleh Akhavan-Niaki; Ali Ghabeli Juibary
Journal:  Iran J Pediatr       Date:  2011-03       Impact factor: 0.364

6.  Frequency of allele variations in the CFTR gene in a Mexican population.

Authors:  Consuelo Cantú-Reyna; Roberto Galindo-Ramírez; Mercedes Vázquez-Cantú; Lorenza Haddad-Talancón; Willebaldo García-Muñoz
Journal:  BMC Med Genomics       Date:  2021-11-05       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.